Stepronin is clinically used as an expectorant. It inhibits airway secretion in vitro by both decreasing Cl- secretion from epithelial cells and mucus glycoprotein secretion from submucosal glands. The mucolytic activity of stepronine does not involve the gastric mucous coating and that the drug does not exert adverse effects on the gastric mucosa. It is a new chemical immunosuppressant drug, which has the effect of preventing graft-versus-host-disease (GVHD) in a mouse model. The mechanism by which this compound acts as an immunosuppressant appears to be similar to cyclosporine A (CyA), although, in contrast to CyA, it is not toxic for animals and humans. Stepronin has an antiviral effect as well and is able to block, indirectly, the human immunodeficiency virus–1 (HIV-1) replication in mononuclear cells in vitro.

Butidrine is naphthalenemethanol devivative with β-adrenolytic, antiarrhythmic, and local anesthetic properties having sympatholytic and antiarrhythmic effects comparable to those of pronethalol and propranolol.

Impacarzine is cyclic urea derivative patented by pharmaceutical company Asta-Werke A.-G. as antiviral agent. In preclinical models Impacarzine gave 25% protection to mice infected with Influenza A2/Hongkong virus.

Thioglycolic acid (TGA, also known as MERCAPTOACETIC ACID) is widely used in the hairdressing industry, which mostly caters to women. TGA has been reported to impair several organs, especially reproductive ones such as testes and ovaries. Thioglycolates (the salt forms of TGA) was shown to penetrate the skin and distribute to the kidneys, lungs, small intestine, and spleen; excretion is primarily in the urine. In addition, thioglycolates can be skin irritants of an animal and can be sensitizers.

Perflenapent (EchoGen, Sonus Pharmaceuticals, Bothel, WA, USA) is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation. EchoGen comprises liquid droplets of dodecafluoropentane stabilised by polyfluoroalkyl(polyoxyethylene) ethanol and dispersed in an aqueous formulation containing sucrose. Dodecafluoropentane is the chemical name used to reflect the perflenapent/perflisopent mixture. Following activation and administration of EchoGen, dodecafluoropentane microbubbles are formed. EchoGen should only be used in patients where the study without contrast enhancement is inconclusive. The European Commission has approved SONUS Pharmaceuticals' EchoGen (perflenapent emulsion) in all 15 countries of the European Union. EchoGen is a fluorocarbon-based ultrasound contrast agent which has been approved as a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease who have had previous inconclusive non-contrast studies. Additional approved labeling in the EU states that the use of EchoGen in spectral and color Doppler studies was shown to enhance the visualization of blood flow across mitral, aortic and tricuspid valves in a subset of patients. In 2000 SONUS Pharmaceuticals withdrew the NDA for EchoGen in the USA.